EGFR and diffuse large B-cell lymphoma: Proteins that are generally more highly expressed in one entity compared to others included well-known cases such as TOP2A, DOCK2, Il16, and BTK for DLBCL and EGFR, CRYAB, and GFAP for GBM (Fig. 5A,B), several of which are also drug targets in these entities (Appendix Fig. S3).